The next generation of genetically modified (GM) plants may make products headed for the pharmacy shelves. Researchers and biotech companies have begun engineering plants to produce a wide variety of pharmaceuticals such as edible vaccines, therapeutic proteins and plant-produced antibodies.
This article from the Pew Initiative on Food and Biotechnology describes how far the technology has progressed, and looks into the pros and cons of so-called 'pharming'.
While the technology's developers hope GM plants will provide a cheaper way to produce drugs, consumer advocates argue that current regulatory system isn't up to the challenge of plant-based pharmaceuticals, and environmentalists are concerned that the proteins produced could accidentally make their way into the food supply.
Link to full AgBiotech Buzz article
Add your comment
All comments are subject to approval and we reserve the right to edit comments containing inappropriate/unsuitable language. SciDev.Net holds copyright for all material posted on the website. Please see terms of use for further details.
You need to be signed in to post a comment or to email a consenting comment author. Please sign in or sign up.